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Abstract
In this commentary, we elaborate on the main points that Karamouzian and colleagues have made about HIV 
data scarcity in Middle Eastern and North African (MENA) countries. Without accessible and reliable data, no 
epidemic can be managed effectively or efficiently. Clearly, increased investments are needed to bolster capabilities 
to capture and interpret HIV surveillance data. We believe that this enhanced capacity can be achieved, in part, 
by leveraging and repurposing existing data platforms, technologies and patient cohorts. An immediate modest 
investment that capitalizes on available infrastructure can generate data on the HIV burden and spread that can 
be persuasive for MENA policy-makers to intensify efforts to track and contain the growing HIV epidemic in this 
region. A focus on key populations will yield the most valuable data, including among men who have sex with 
men (MSM), transgender women and men, persons who inject drugs (PWIDs), female partners of high risk men 
and female sex workers.
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The HIV/AIDS pandemic is now well into its fourth decade. Local conditions differ and regional epidemics have diverging trajectories. Since the antiretroviral 
and infrastructure investments spurred by the massive HIV 
programs began in 2003-2004—such as the US President’s 
Emergency Plan for AIDS Relief (PEPFAR) and the 
Global Fund to Fight AIDS, Tuberculosis and Malaria—
HIV incidence and AIDS-related death rates have fallen 
significantly in some of the worst-affected areas of the world 
(ie, sub-Saharan Africa, Southeast Asia). In contrast, HIV 
has steadily risen in what were previously thought to be 
low-risk, low prevalence zones (ie, Eastern Europe, Central 
Asia, Middle East and North Africa [MENA]).1 Karamouzian 
et al, in their recent editorial, offer insights into one of the 
key reasons for this epidemiologic discrepancy: poor data 
availability and integrity.2 The authors identify some of the 
major challenges to capturing and validating HIV surveillance 
data in the MENA region; including the persistence of violent 
conflict, lack of political will, and stigmatization of the most-
at-risk populations. 
Although there are some common challenges that stretch 
across the region, MENA countries comprise a complex mosaic 
of populations and policies. Thus, each country requires 
a tailored approach to improving HIV surveillance and 
prevention efforts. Iran, for example, hosts the highest number 
of cases in the region (Figure) and is battling an epidemic 
driven primarily by injection drug use.1,3,4 It has implemented 
a set of inconsistent policies that has had both progressive and 
regressive impacts on the public health community’s efforts to 
control HIV transmission. For example, while Iran has served 
as a model for other countries in its successful implementation 
of harm-reduction policies and deployment of peer education 
programs and needle exchange centers,5 national laws have 
also been passed that are severely punitive against persons 
who inject drugs (PWIDs) and men who have sex with men 
(MSM).6 Saudi Arabia, in contrast to Iran, has among the 
lowest registered HIV cases in the world and leads the Arab 
Strategic Framework for the Response to HIV and AIDS,7 
but pursues policies that confine and deport any incident 
cases among its sizeable guest worker population.8,9 Persons 
from the large guest working population who acquire HIV 
in the more tolerant United Arab Emirates still face the same 
expulsion policy. Conflicting policies and practices are not 
unique to specific countries, as competing priorities can yield 
contradictory approaches to societal problems, particularly in 
a region where traditional and modernizing influences create 
divergent sentiments.
Advocates for enhanced HIV prevention, care, and treatment 
services in the MENA region face a conundrum: they require 
reliable data in order to persuade governments to pursue 
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rational and consistent HIV prevention policies and invest 
more resources for HIV surveillance. How, then, can national 
policy makers in the MENA region be convinced that HIV 
is a public health threat that demands increased vigilance 
without verifiable evidence to justify such investments? 
Karamouzian et al suggest some initial steps toward tackling 
this problem, including the amplification of outreach efforts 
to regional refugees, MENA research training programs 
and cooperative initiatives to combat HIV-related stigma.2 
Although these measures are necessary for a comprehensive 
strategy to rein in a worsening regional epidemic, they 
do not address the primary challenge of igniting stronger 
political will among regional health and finance leaders. In 
this commentary, we seek to enhance the excellent points 
presented by Karamouzian et al by suggesting additional ideas 
on how to create conditions that will promote national and 
international investments into enhanced data capture and 
validation systems that will ultimately lead to better control of 
HIV spread in the MENA region.
Leverage Existing Data Systems and Public Health 
Infrastructures
New technologies, processes and protocols need not be 
invented de novo for HIV surveillance. There is already a 
network of extant surveillance, clinical and research data 
repositories, along with information-sharing agreements 
across the MENA region. There are several models from 
international governing bodies, national registries and not-
for-profit organizations. A key example is the World Health 
Organization (WHO) Global Influenza Program that provides 
virologic and epidemiologic surveillance data on circulating 
strains and transmission patterns to member nations.10 
Regional laboratories and sentinel sites that feed into this 
network have formed the basis for additional networks and 
collaborations that include the International Severe Acute 
Respiratory and Emerging Infection Consortium (ISARIC) 
and the Eastern Mediterranean Acute Respiratory Infection 
Surveillance Network (EMARIS).11,12 Since the emergence of 
the Middle East respiratory syndrome coronavirus (MERS-
CoV) in 2012 on the Arabian Peninsula,13 these networks have 
been exploited for surveillance and monitoring of this and 
other novel respiratory pathogens. Laboratory infrastructures, 
database architectures, agreement frameworks, and 
operational logistics that have already been worked out for 
severe acute respiratory illnesses are models for how to handle 
regional data collection for HIV and other infectious diseases. 
Varying conditions have different epidemiologic features, 
but all require a network of laboratories, clinical centers and 
tracking systems under a coherent regional network plan. 
Other examples outside the MENA region have shown 
that laying a broad foundation for disease surveillance 
can pay dividends for the control of epidemics of disparate 
nature. Amid the 2014 West African Ebola outbreak, the 
situation became frightening when this lethal filovirus 
appeared in Lagos, Nigeria, Africa’s most populous city with 
a 2016 population estimated by the National Population 
Commission of Nigeria to be 21 million persons. In spite of 
the high population density and unexpected emergence of 
Ebola in West Africa, Nigeria was able to halt its outbreak to 
20 cases and eight deaths, far short of the tens-of-thousands of 
infections in the hardest hit countries of Guinea, Sierra Leone 
and Liberia.14 There were a number of reasons for Nigeria’s 
success. Paramount among them was the government’s ability 
to quickly turn its polio eradication program infrastructure 
to the task of containing Ebola transmission.15 If such a quick 
pivot can be made in the flux of a dynamic and widespread 
regional outbreak, then the same model could be adapted 
to the setting of the more slowly evolving and concentrated 
epidemic of HIV in the MENA region. 
Figure. Distribution of Population, People Living With HIV/AIDS (B) and 
Published HIV-1 Sequences From Countries in the MENA Region.
The total population (World Bank) (A), people living with HIV/AIDS 
(UNAIDS) (B), and number of sequences publicly available (GenBank) (C) 
in 2015 for the 25 countries in the MENA region. No HIV burden estimates 
(B) were available in 2015 for Bahrain, Iraq, Jordan, Kuwait, Libya, Oman, 
Qatar, Saudi Arabia, Syria, Turkey, and the UAE. No HIV sequences were 
publicly available for Bahrain, Iraq, Jordan, Oman, Qatar, Syria, and the 
UAE.
Abbreviations: MENA, Middle East and North Africa; UAE, United Arab 
Emirates.
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Intensify the Follow-up, Care and Data Collection Efforts 
for Known HIV Cases 
Despite a paucity of HIV surveillance data, Ministries of 
Health in the MENA region have the capability to track 
known HIV cases through their typically centralized care and 
treatment services.4 Still, these same countries collectively 
have the lowest antiretroviral coverage rates in the world, 
with an average of 17% on treatment, partially explaining the 
region’s 20-fold increase in AIDS-related deaths in the past 
10 years.1 Although a centralized health system may have an 
effect of facilitating stigmatization, public health workers can 
also capitalize on this feature to capture more robust data and 
improve outcomes for their HIV infected patients. Although 
intensified surveillance and massively expanded HIV testing 
will be a key aspect to controlling the epidemic, a failure to 
capture key data on risk behaviors, treatment adherence, drug 
resistance and host and virus genetic sequences from known 
populations is a missed opportunity. Such data can inform 
policies to lower HIV incidence and mortality by helping 
target resources to where the largest impact could be expected, 
eg, MSM and sex workers (female, male, or transgender). 
The MENA region is comprised of countries with a wide 
range of financial resources and technical capacity. Yet most 
of the data, particularly viral sequence diversity, comes 
from three middle-income countries: Algeria, Morocco, 
and Iran (Figure).16 Recently, several MENA countries have 
undertaken initiatives that put their genomic technologic 
prowess on full display. The Qatar Genome Program, for 
example, aspires to generate personalized genomic data for 
its entire population as part of a national precision medicine 
initiative.17 In an initial demonstration project, the program 
sequenced 1000 human genomes and uncovered more than 
20 million polymorphisms to analyze. Yet, in the face of this 
titanic effort to sequence human genomes, not a single viral 
sequence from the approximately 100 documented HIV cases 
in Qatar has ever been entered into GenBank, as of April 
2017.18 This incongruity argues that the tools and funding 
are available, but the political will is lacking for collecting 
basic virologic information on recognized HIV cases. The 
key will be in convincing policy-makers in the region that 
obtaining key data on subtype diversity and antiretroviral 
resistance mutations is straightforward and could guide the 
epidemiologic and clinical knowledge relevant for both HIV 
prevention and clinical care for persons living with HIV in 
the region. 
Engaging Key Populations 
Throughout the history of the HIV/AIDS pandemic, 
key populations—including PWIDs, MSM, transgender 
populations, and female sex workers—have been subject to 
discrimination, stigmatization and criminalization. These 
policies drive away stigmatized subgroups and make it harder 
to engage them in the vital therapeutic and prevention alliances 
that enable implementation of successful health programs. 
Just as some health ministries outside the MENA region have 
adopted best practices from countries like Iran and Morocco,5 
the MENA region could also learn lessons from countries 
with similar cultural conditions on how to best engage and 
reduce high-risk behaviors among key populations within 
their borders. One notable example comes from Nigeria, 
where homosexuality remains criminalized,19 yet also has 
well-established programs that collect data from and provides 
services to MSM populations.20 Given the cultural climate and 
standing laws in Nigeria, it is not surprising that this group 
has been difficult to contact, trace and recruit into research 
and treatment cohorts. Hence, researchers and public health 
practitioners have recruited key community leaders to lead 
the outreach efforts to members of their communities. It is 
likely that, in MENA countries, high-risk social and sexual 
networks are also best accessed and followed with the help of 
community leaders and/or peers already integrated into these 
networks; and that these efforts can be best operationalized 
with respondent-driven sampling, snowball sampling 
strategies or post-testing counseling of newly diagnosed 
persons. 
Conclusion
MENA investigators have shown that both key HIV-
uninfected, vulnerable populations and HIV-infected persons 
can be studied with modern field and clinical methods. 
Prospective follow-up is feasible, molecular phylogeny is 
obtainable and interpretable for understanding transmission 
dynamics and surveillance can guide improved policies.21-26 
History teaches time and time again that epidemics ignored 
are epidemics unleashed. A dearth of relevant data will simply 
misrepresent the true epidemic profile, misleading public 
health and clinical practitioners and policy-makers. Europe 
and North America, with decades of HIV successes and 
failures, can be allies, given their imperative to support global 
health for both humanitarian and self-serving interests.27 
It has become clear that no region, no culture, and no 
population is immune to the emergence and expansion 
of an HIV epidemic. Despite bold claims in the past that 
HIV/AIDS is not a problem for predominantly Muslim 
nations, all indicators have pointed to rising HIV incidence 
and mortality, both in absolute numbers and in relation to 
the rest of the world. In the current commentary, we have 
elaborated on the argument made by Karamouzian et al 
that a key measure for preventing a concentrated epidemic 
from becoming a disseminated one is to intensively and 
consistently collect population-based data.2 Although 
recognition and characterization of a problem is the first step 
toward its resolution, it is meaningless if that knowledge does 
not translate into action. Action starts with active surveillance 
efforts and meaningful investments into regional networks 
and national programs, such as those that have been outlined 
in the course of this commentary. Efficiencies can evolve from 
repurposing existing tools, using translatable data-collection 
platforms and partnerships and adopting best surveillance 
practices. The story of HIV can be traced along a convoluted 
path of both maladaptive decisions and farsighted strategies. 
MENA countries have the opportunity now to move from the 
former to the latter, turning the tide of a potentially worsening 
public health crisis. 
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